Redeye views today’s news from Kontigo Care as very positive; the technology developed by Kontigo Ca...
Redeye updates its estimates on Safello before the company’s Q3 report.
Fortsatt stark efterfrågan Midsummer rapporterade en omsättning på 16,0 mkr i Q3’22, klart lägre än ...
Rapportkommentar Guards rapport för det tredje kvartalet var enligt våra förväntningar – relativt od...
Redeye comments on Mestro's Q3 report, which was more or less in line with our CARR forecast.
Redeye comments on Better Collective’s Q3-results which came in somewhat lower than expected while t...
Redeye's first comments on the Q3 report this morning.
Redeye concludes that Q3 showed weak financials due to delay in the Saudi order, higher OPEX due to ...
Redeye comments on Embracers Q2 2022/23 report. Net sales came in 4% higher than our estimates, whil...
Redeye comments on EG7’s Q3-results which came in much stronger than expected thanks to strong perfo...
During Q3, Modelon announced the public cloud version of Impact.
Redeye is pleased that Paxman announced yesterday that the Paxman Limb Cryocompression System (PLCS)...
Redeye updates its estimates and base case following Sozap’s Q3 report, which showed lower sales and...
Redeye updates its estimates and fair value range following Arise’s Q3 report, where reported EBITDA...
Redeye’s expectations are again outdone as Bong is posting solid Q3 numbers.
AcuCorts användarvänliga kortisonfilm Zeqmelit har erhållit godkännande inom flertalet nordiska länd...
Redeye has a mildly positive take on today’s news that Nanexa has reached a settlement with Vitrivax...
Redeye comments on Scandion Oncology’s Q3 2022 report, some one month after the company has recruite...
Omsättning i linje med estimat Omsättning i kvartalet uppgick till 617 mkr, vilket motsvarar en till...
